Figure 1From: Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing intervalStudy disposition. *Eight patients in the safety population were not part of the prospectively defined ITT population (n = 67) for which the primary endpoint, relapse incidence, was calculated. Twenty patients in the safety population, versus 12 patients in the ITT population, relapsed.Back to article page